Piperlongumine promotes death of retinoblastoma cancer cells.

Détails

Ressource 1Télécharger: 33953844_BIB_7F61A64ED104.pdf (2934.09 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_7F61A64ED104
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Piperlongumine promotes death of retinoblastoma cancer cells.
Périodique
Oncotarget
Auteur⸱e⸱s
Allaman-Pillet N., Schorderet D.F.
ISSN
1949-2553 (Electronic)
ISSN-L
1949-2553
Statut éditorial
Publié
Date de publication
27/04/2021
Peer-reviewed
Oui
Volume
12
Numéro
9
Pages
907-916
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Retinoblastoma is the most common pediatric intraocular malignant tumor. While retinoblastoma initiation is triggered by the inactivation of both alleles of the retinoblastoma tumor suppressor gene (RB1) in the developing retina, tumor progression requires additional epigenetic changes, retinoblastoma genomes being quite stable. Although the management of RB has recently improved, new therapeutic agents are necessary to improve the treatment of advanced forms of retinoblastoma. In this report, we analyzed the pro-death effect of piperlongumine (PL), a natural compound isolated from Piper longum L., on two human retinoblastoma cell lines, WERI-Rb and Y79. The effects of PL on cell proliferation, cell death and cell cycle were investigated. PL effectively inhibited cell growth, impacted the cell cycle by decreasing the level of cyclins and CDK1 and increasing CDKN1A and triggered a caspase-3 independant cell death process in which reactive oxygen species (ROS) production is a major player. Indeed, PL toxicity in retinoblastoma cell lines was inhibited by a ROS scavenger N-acetyl-l-cysteine (NAC) treatment. These findings suggest that PL reduces tumor growth and induces cell death by regulating the cell cycle.
Mots-clé
cancer, piperlongumine, programmed cell death, retinoblastoma
Pubmed
Open Access
Oui
Création de la notice
24/05/2021 13:21
Dernière modification de la notice
23/01/2024 7:28
Données d'usage